

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 6 Mar 2020 14:50:15 +0000  
**To:** (b) (6)  
**Subject:** FW: Developing Immunity to SARS-CoV-2 and Ivlg

Please respond to this person.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Dr. Art Kamm <art@kammconsultinginc.com>  
**Sent:** Friday, March 6, 2020 7:47 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E]  
(b) (6)>  
**Subject:** Developing Immunity to SARS-CoV-2 and Ivlg

Dear Dr. Fauci and Dr. Lane:

I have been following the growing international outbreak of COVID-19 and wanted to share a thought with you, understanding that this may have already been thought of. My early academic research (reference provided, PNAS) involved cancer immunology where it contributed to a growing body of information that certain tumor cells could possess unique surface antigens that could be used for immunologic therapy (<https://www.pnas.org/content/pnas/75/12/5912.full.pdf>). My career then took me to executive and senior executive/corporate officer positions in publicly-held pharmaceutical corporations (Glaxo and Salix, respectively) overseeing R&D of therapeutic agents. My experience has included both pharmaceuticals and biologics.

(b) (6)

Our current understanding of COVID-19 mortality is that it appears to be concentrated in the elderly and those with underlying medical conditions. In healthy individuals (although still early) it appears that many of